FDA Grants Approval for Propranolol Hydrochloride ANDA219165
The FDA has granted approval for the ANDA219165 application for Propranolol Hydrochloride submitted by PAI Holdings.
Company
Beta-blocker
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of PAI Holdings' ANDA for Propranolol Hydrochloride introduces a generic competitor into the beta-blocker market, which could disrupt pricing and market share dynamics. Portfolio teams must evaluate the potential impact on existing propranolol products and adjust strategies accordingly.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from PAI Holdings and competitors.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.